Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors

NCT07689812 is registered in ClinicalTrials.gov with Natera, Inc. as lead sponsor.

NCT NCT07689812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07689812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Natera, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
March 31, 2034
Enrollment
920 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, advanced solid tumors cancer, crc, dmmr colorectal cancer, melanoma (skin cancer), melanoma (skin) stage iv, metastatic solid tumors, msi high colorectal cancer, nsclc, nsclc (advanced non-small cell lung cancer), nsclc (non-small cell lung cancer), nsclc (non-small cell lung carcinoma), rcc, rcc, renal cell cancer, solid tumors